Standard BioTools Insider Filing: 94,592 RSUs, 188,490 Options Awarded

Rhea-AI Filing Summary

Standard BioTools Inc. (LAB) – Form 4 insider transaction filed 06/24/2025

Director Thomas D. Carey reported two equity awards dated 06/20/2025:

• 94,592 Restricted Stock Units (RSUs) that vest in full on the earlier of 20 Jun 2026 or one day prior to the company’s next annual meeting, contingent on continued service. Each RSU converts into one share of common stock upon vesting.
• 188,490 stock options with a $1.05 exercise price, becoming exercisable in 12 equal monthly installments beginning 20 Jul 2025 and expiring 20 Jun 2035, also subject to continued service.

Following these grants, Carey’s direct beneficial ownership stands at 194,058 common shares. No dispositions were reported; the grants were acquired at $0 cost (for RSUs) and standard option pricing applies upon exercise. The filing does not reference any 10b5-1 trading plan.

The reported awards reflect routine director compensation and do not involve open-market purchases or sales; therefore, immediate dilution or cash impact to shareholders is negligible. Investors may view the transaction primarily as a governance disclosure rather than a signal of near-term fundamentals.

Insights

Financial Analyst

TL;DR: Routine director equity grants; no market-moving information, neutral cash impact.

The Form 4 shows standard annual equity compensation—a sub-$200k share grant and 188k options at $1.05 strike—to a non-executive director. There is no purchase of shares with personal funds, so alignment signals are modest. Because the RSUs vest over one year and options vest monthly over 12 months, share count dilution is both small and spread over time. No other trading activity is disclosed, and ownership after the grant totals 194,058 shares, a minimal percentage of LAB’s outstanding shares. Overall, I consider the filing neutral for valuation and liquidity.

Corporate Governance Expert

TL;DR: Filing confirms standard board compensation practices; governance compliant.

From a governance standpoint, the company is transparent in disclosing equity incentives. The RSU one-year cliff and 10-year option term with monthly vesting match common small-cap board compensation structures and encourage retention. No 10b5-1 plan was marked, indicating discretionary grants rather than pre-planned trades. There are no red flags such as accelerated vesting or repricing. Hence, I classify the impact as neutral for shareholders.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Carey Thomas D.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	188,490	$0.00	--
Grant/Award	Common Stock	94,592	$0.00	--

Holdings After Transaction: Stock Option (Right to buy) — 188,490 shares (Direct); Common Stock — 194,058 shares (Direct)

Footnotes (1)

1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 20, 2026 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. The Option becomes exercisable in twelve equal monthly installments beginning on July 20, 2025, subject to the Reporting Person's continued service through the applicable vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carey Thomas D.

(Last) (First) (Middle)

C/O STANDARD BIOTOOLS INC.

2 TOWER PLACE, STE 2000

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		A		94,592(1)	A	$0	194,058	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$1.05	06/20/2025		A		188,490		(2)	06/20/2035	Common Stock	188,490	$0	188,490	D

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 20, 2026 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

2. The Option becomes exercisable in twelve equal monthly installments beginning on July 20, 2025, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Thomas D. Carey by Tomone Tanaka, Attorney-in-Fact	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many RSUs did Director Thomas D. Carey receive according to LAB's latest Form 4?

He was granted 94,592 Restricted Stock Units on 06/20/2025.

What is the exercise price and size of the stock option grant reported for LAB?

Carey received 188,490 options with a $1.05 exercise price.

When do the newly granted LAB stock options become exercisable?

They vest in 12 equal monthly installments starting 20 Jul 2025 and expire 20 Jun 2035.

What is Thomas D. Carey's total LAB share ownership after the reported transactions?

He beneficially owns 194,058 common shares directly following the grants.

Do the reported transactions involve any open-market purchases or sales of LAB stock?

No. The Form 4 only discloses equity awards (RSUs and options); no shares were bought or sold on the market.